Dataset Information


Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor ?B signaling.

ABSTRACT: Acute kidney injury is associated with a significant inflammatory response that has been the target of renoprotection strategies. Epoxyeicosatrienoic acids (EETs) are anti-inflammatory cytochrome P450-derived eicosanoids that are abundantly produced in the kidney and metabolized by soluble epoxide hydrolase (sEH; Ephx2) to less active dihydroxyeicosatrienoic acids. Genetic disruption of Ephx2 and chemical inhibition of sEH were used to test whether the anti-inflammatory effects of EETs, and other lipid epoxide substrates of sEH, afford protection against cisplatin-induced nephrotoxicity. EET hydrolysis was significantly reduced in Ephx2(-/-) mice and was associated with an attenuation of cisplatin-induced increases in serum urea nitrogen and creatinine levels. Histological evidence of renal tubular damage and neutrophil infiltration was also reduced in the Ephx2(-/-) mice. Likewise, cisplatin had no effect on renal function, neutrophil infiltration, or tubular structure and integrity in mice treated with the potent sEH inhibitor 1-adamantan-1-yl-3-(1-methylsulfonyl-piperidin-4-yl-urea) (AR9273). Consistent with the ability of EETs to interfere with nuclear factor-?B (NF-?B) signaling, the observed renoprotection was associated with attenuation of renal NF-?B activity and corresponding decreases in the expression of tumor necrosis factor (TNF) ?, TNF receptor (TNFR) 1, TNFR2, and intercellular adhesive molecule-1 before the detection of tubular injury. These data suggest that EETs or other fatty acid epoxides can attenuate cisplatin-induced kidney injury and sEH inhibition is a novel renoprotective strategy.


PROVIDER: S-EPMC3362876 | BioStudies | 2012-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

2013-01-01 | S-EPMC3834146 | BioStudies
2016-01-01 | S-EPMC4699807 | BioStudies
2009-01-01 | S-EPMC2724109 | BioStudies
2014-01-01 | S-EPMC3981766 | BioStudies
2012-01-01 | S-EPMC3349654 | BioStudies
2017-01-01 | S-EPMC5446112 | BioStudies
2020-01-01 | S-EPMC7242354 | BioStudies
1000-01-01 | S-EPMC3107315 | BioStudies
2006-01-01 | S-EPMC2072806 | BioStudies
2017-01-01 | S-EPMC5873293 | BioStudies